Company intelligence / Profile preview

Bright Minds Biosciences

New York, New York, United States

Ownership: Private
Employees: ~25
Development stage: Other

Overview

Lead program BMB-101 has completed Phase 1 studies for an undisclosed seizure disorder, demonstrating functional selectivity at 5-HT2C with anticipated improved safety. Other pipeline assets are preclinical for neuropsychiatric and neurology indications[1][4][7].

Therapeutic areas: NeurologyPsychiatry
Modalities: Small molecule
Industry: Biotech

Partnerships

National Institutes of Health (NIH)University of Texas Medical BranchMedical College of Wisconsin

Beyond the preview

Go deeper on Bright Minds Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bright Minds Biosciences.

Explore the full profile